Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Analysis shows Gilead’s recently approved drug for HIV prevention, Yeztugo, has the potential to transform the PrEP sector in the US.

Sanofi is to invest up to $25m in Adagene, which will enable the latter to fund its R&D efforts, including clinical development of muzastotug.

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission for Ziihera for biliary tract cancer.

US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance broke a 50-50 deadlock in the US Senate.

Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the potential.

Piramal Pharma invests $90m to expand its two US facilities, enhancing manufacturing capabilities for sterile injectables and ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...